Three weeks after giving birth, you are hit with a blinding headache and fading vision. The next available appointment with your doctor is two weeks away. You finally go to your doctor, and your blood pressure has already reached a dangerous level without you even realizing.
The solution is straightforward. A home blood pressure monitor costs between $69 and $169. Yet most insurers will not cover it because many states do not require them to. The result is predictable: People continue to face life-threatening complications even though they are very much preventable.
Problem magnitude
Hypertension affects roughly one in three American adults and costs the nation $131 billion each year in health care services, medications, and lost productivity. The risk of hypertension becomes even greater during pregnancy and the postpartum period.
Up to 10 percent of pregnant individuals experience high blood pressure, representing the highest rate in the past 25 years. If it goes uncontrolled, hypertension can develop into preeclampsia or eclampsia and may lead to strokes, heart attacks, or death. Most importantly, 97 percent of these deaths are preventable. Research demonstrates that home blood pressure monitoring is highly effective.
Boston Medical Center implemented a remote monitoring program for postpartum patients. Before this program began, only 13 percent of high-risk patients had their blood pressure checked within a week after delivery. After distributing the monitors, that figure increased to 79 percent. Even more significantly, the rate of severe hypertension fell from 18.4 percent to 5.9 percent. This represents a real difference between patients returning home with confidence and patients leaving with risk and uncertainty.
The financial case is equally compelling. An economic analysis showed that remote monitoring saves money in 99.28 percent of cases, and avoiding a single hospital readmission costs only $145. In comparison, one hospitalization for preeclampsia can cost between $15,000 and $50,000.
The equity issue requires particular attention. Black women experience maternal mortality at rates three to four times higher than white women and receive less blood pressure monitoring during routine clinic visits. When Boston Medical Center provided home monitors, this gap was filled. Black patients went from being monitored 41 percent of the time to 93 percent, reaching the same level of care as white patients. Home monitoring removes barriers such as transportation, childcare responsibilities, work schedules, and biases present in clinical settings.
National momentum and remaining gaps
Forty-two states currently provide Medicaid coverage for home blood pressure monitors, and 25 of those states also include clinical support services such as provider training, data interpretation, and patient education. States such as Michigan, Maryland, New Jersey, and Georgia have already recognized these devices as an essential part of health care infrastructure. Despite this progress, significant gaps remain. Most importantly, not all states have this health policy. Some states restrict coverage to one monitor every five years. Others require prior authorization, which slows access to care. The wide variation in state policies shows that evidence-based best practices have not yet been adopted nationwide; however, the first priority is to have some extent of the policy in each state.
Addressing reasonable concerns
Some people question whether home monitors are accurate enough. The solution is simple: Coverage should be limited to clinically validated devices. Monitors that are not validated can fail to detect high blood pressure in 48 to 80 percent of cases, making validation essential. Professional organizations already maintain lists of approved devices specifically intended for use during pregnancy.
Another concern is that patients may not use the monitors consistently. Research shows the opposite: 93 percent of patients with home monitors submit readings, compared with only 33 percent who attend in-person visits. Patients are more likely to follow monitoring schedules at home rather than navigating clinic appointments, childcare responsibilities, and work obligations.
A third counterargument points to free blood pressure checks at pharmacies. However, only a single reading at a pharmacy will provide limited clinical value. Effective monitoring is multiple readings over time, professional interpretation, and follow-up care. This level of comprehensive management cannot be achieved through occasional pharmacy visits.
The path forward
States should require comprehensive coverage that includes clinically validated devices at no cost to patients. Forty-two states have already adopted this approach. The evidence for effectiveness and cost-efficiency is clear, and the steps for implementation are well established. What remains is a question of political commitment.
The central question for policymakers is whether we can afford to leave this need unaddressed. The case is clear and compelling: The science, the economics, and the equity considerations all support action. Every state legislature should recognize universal coverage for home blood pressure monitoring as a critical investment in saving lives, advancing health equity, and improving the efficiency of the health care system.
Soneesh Kothagundla is a health policy advocate.
